Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer
The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]
Quality of life outcomes similar for cabozantinib and everolimus
Data from the phase 3 METEOR trial published in the Journal [...]
Combination immunotherapy: the new standard of care for metastatic kidney cancer
The following video interviews discuss combinations of immunotherapy drugs and [...]
New Cancer Drugs Fund benefiting thousands of patients and releasing £140m for the NHS
NHS England have released an update on the new Cancer [...]
The benefits of immunotherapy combinations
This article, published in Nature just before Christmas, gives a [...]
Cabozantinib more effective than everolimus for treatment of kidney cancer bone metastases
Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in people [...]
Crizotinib shows promise in type 1 papillary kidney cancer
Papillary kidney cancer is a rare subtype of renal cell [...]
Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA
The US Food and Drug Administration (FDA) have granted Breakthrough [...]
Sequencing of treatments for advanced kidney cancer remains uncertain
There are now a number of licensed drug options available [...]
A new class of anti-cancer drug for kidney cancer shows promise
Researchers in America are looking at a new class of [...]
